Hepatitis C: From inflammatory pathogenesis to anti-inflammatory/hepatoprotective therapy by Li, Hu et al.
Hepatitis C: From inflammatory pathogenesis to anti-
inflammatory/hepatoprotective therapy
Hu Li, Meng-Hao Huang, Jian-Dong Jiang, Zong-Gen Peng
Hu Li, Jian-Dong Jiang, Zong-Gen Peng, Institute of 
Medicinal Biotechnology, Chinese Academy of Medical Sciences 
and Peking Union Medical College, Beijing 100050, China
Meng-Hao Huang,  Division of Gastroenterology and 
Hepatology, Department of Medicine, Indiana University School 
of Medicine, Indianapolis, IN 46202, United States
Jian-Dong Jiang, Institute of Materia Medica, Chinese Academy 
of Medical Sciences and Peking Union Medical College, Beijing 
100050, China
ORCID number: Hu Li (0000-0002-7609-9399); Meng-Hao 
Huang (0000-0002-2389-8680); Jian-Dong Jiang (0000-0002 
-1138-2943); Zong-Gen Peng (0000-0001-7662-6892).
Author contributions: All the authors contributed to the search 
and analysis of the literature and to the writing of the paper.
Supported by CAMS Innovation Fund for Medical Sciences, 
No. 2017-I2M-3-012; National Natural Science Foundation 
of China, No. 81773788 and 81621064; and National Mega-
Project for “R&D for Innovative Drugs”, Ministry of Science and 
Technology, China, No. 2018ZX09711001-003-010.
Conflict-of-interest statement: No potential conflicts of interest.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Manuscript source: Unsolicited manuscript
Corresponding author to: Zong-Gen Peng, PhD, Professor, 
Institute of Medicinal Biotechnology, Chinese Academy of Medical 
Sciences and Peking Union Medical College, No. 1, Tiantan Xili, 
Beijing 100050, China. pengzonggen@imb.pumc.edu.cn
Telephone: +86-10-63166129
Fax: +86-10-63017302
Received: October 19, 2018
Peer-review started: October 19, 2018
First decision: November 22, 2018
Revised: November 27, 2018 
Accepted: November 30, 2018   
Article in press: November 30, 2018
Published online: December 21, 2018
Abstract
Hepatitis C virus (HCV) infection commonly causes 
progressive liver diseases that deteriorate from 
chronic inflammation to fibrosis, cirrhosis and even to 
hepatocellular carcinoma. A long-term, persistent and 
uncontrolled inflammatory response is a hallmark of these 
diseases and further leads to hepatic injury and more 
severe disease progression. The levels of inflammatory 
cytokines and chemokines change with the states of 
infection and treatment, and therefore, they may serve 
as candidate biomarkers for disease progression and 
therapeutic effects. The mechanisms of HCV-induced 
inflammation involve classic pathogen pattern recognition, 
inflammasome activation, intrahepatic inflammatory 
cascade response, and oxidative and endoplasmic 
reticulum stress. Direct-acting antivirals (DAAs) are the 
first-choice therapy for effectively eliminating HCV, but 
DAAs alone are not sufficient to block the uncontrolled 
inflammation and severe liver injury in HCV-infected 
individuals. Some patients who achieve a sustained 
virologic response after DAA therapy are still at a 
long-term risk for progression to liver cirrhosis and 
hepatocellular carcinoma. Therefore, coupling with anti-
inflammatory/hepatoprotective agents with anti-HCV 
effects is a promising therapeutic regimen for these 
patients during or after treatment with DAAs. In this 
review, we discuss the relationship between inflammatory 
mediators and HCV infection, summarize the mechanisms 
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of HCV-induced inflammation, and describe the potential 
roles of anti-inflammatory/hepatoprotective drugs with 
anti-HCV activity in the treatment of advanced HCV 
infection.
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Core tip: Inflammatory responses triggered by hepatitis 
C virus (HCV) infection lead to severe progressive liver 
diseases. Some inflammatory cytokines and chemokines 
may serve as biomarkers for the disease progression and 
therapeutic effect in chronic hepatitis C (CHC) patients. 
The inflammatory pathogenesis in HCV-infected patients 
is complicated, including classic pathogen pattern 
recognition, inflammasome activation, intrahepatic 
inflammatory cascade response, and oxidative and 
endoplasmic reticulum stress. Direct-acting antivirals 
(DAAs) are not sufficient to block the uncontrolled 
inflammation and disease progression in severe CHC 
patients. Therefore, coupling with anti-inflammatory/
hepatoprotective agents with anti-HCV effects is a 
promising therapeutic regimen for advanced HCV-infected 
patients during or after treatment with DAAs.
Li H, Huang MH, Jiang JD, Peng ZG. Hepatitis C: From 
inflammatory pathogenesis to anti-inflammatory/hepatoprotective 




Hepatitis C virus (HCV) belongs to the genus Hepacivirus 
in the family Flaviviridae and is a positive single-
stranded RNA virus that is approximately 9.6 kb. The 
HCV genome encodes three structural (Core, E1 and 
E2) and seven non-structural (NS) proteins (NS1 or 
P7, NS2, NS3, NS4A, NS4B, NS5A and NS5B)[1]. As a 
kind of hepatic tropism virus, HCV mainly replicates in 
the hepatocyte cytoplasm and frequently causes acute 
or chronic hepatitis C (CHC), which has an estimated 
prevalence of 71 million people and is responsible 
for approximately 399000 deaths annually[1,2]. CHC 
patients generally experience liver diseases ranging from 
liver fibrosis and cirrhosis to hepatocellular carcinoma 
(HCC) and suffer from metabolic disorders such as lipid 
abnormalities, steatosis, insulin resistance, and iron load 
dysregulation[3]. These abnormalities are aggravated by 
long-term hepatic inflammatory responses. Upon HCV 
infection, the immune responses in the liver are initiated 
by parenchymal cells (hepatocytes), non-parenchymal 
liver cells [Kupffer cells (KCs) and hepatic stellate cells 
(HSCs)] and immune cells (macrophages, mast cells, 
dendritic cells and natural killer cells) recruited to the 
liver, resulting in the spontaneous elimination of acute 
HCV infection[4]. However, in 70%-80% of cases, the 
immune responses fail to eliminate the virus during the 
acute phase, leading to chronic infection[4]. Persistent 
HCV replication in hepatocytes leads to uncontrolled 
inflammation and chemokine production. The excessive 
cytokines, as inflammatory agents, further cause 
inflammation in the liver, which eventually exacerbates 
tissue damage and liver disease progression[5].
Direct antiviral treatment is undoubtedly the first 
choice for the treatment of HCV infection. Currently, 
several direct-acting antivirals (DAAs) have been 
approved for clinical use, including NS3/4A, NS5A and 
NS5B inhibitors and fixed-dose combined agents[6]. 
The combinational use of these DAAs has become 
the standard treatment regimen for the treatment 
of HCV infection, which greatly improves sustained 
virologic response (SVR) rates to over 90%, shortens 
the treatment duration and reduces adverse effects, 
when compared with the traditional interferon (IFN) 
plus ribavirin treatment[6]. However, HCV is just 
the initiator for pathophysiological processes, while 
persistent inflammatory cytokine storms (known as 
hypercytokinaemia) and HCV-induced hepatocyte 
damage exacerbate the progression of severe liver 
diseases[7-10]. DAAs primarily control viral replication 
but are not sufficient to restore HCV-induced liver 
dyshomeostasis and advanced liver diseases. Clinically, 
there are different conclusions about the contribution 
of current DAA therapy to reducing cirrhosis and 
HCC, and a subset of patients are still subjected to 
the risk of cirrhosis, HCC and liver failure even after 
achieving an SVR[6,7,11]. Given these limitations of 
DAA therapy, anti-inflammatory and hepatoprotective 
drugs with anti-HCV effects become a good choice for 
those individuals. These drugs have advantages in 
suppressing inflammation/oxidative stress, reducing 
hepatocyte injury and alanine aminotransferase (ALT)/
aspartate aminotransferase (AST) levels and preventing 
the development of liver fibrosis[12]. Therefore, although 
anti-inflammatory/hepatoprotective drugs would not 
replace DAAs, they can be used as a supplement to 
DAA therapy for preventing HCV relapse and liver 
disease progression during or after DAA therapy.
HCV INFECTION AND INFLAMMATORY 
MARKERS
Most inflammatory cytokine and chemokine levels are 
positively correlated with the HCV load and decline after 
antiviral therapy. Although the role of inflammatory 
mediators in HCV infection after treatment with DAAs 
has not received much attention, previous research 
still reported that one or more of these inflammatory 
mediators might serve as inflammatory biomarkers 
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in CHC patients (Table 1). For instance, Costantini et 
al[13,14] revealed that several serum mediators, including 
interleukin (IL)-6 and IL-8, C-X-C motif ligand (CXCL)-9, 
CXCL-10, CXCL-12 and macrophage migration inhibitory 
factor (MIF), might be used as potential markers 
for evaluating the progression of chronic hepatitis to 
cirrhosis. Hepatic tumor necrosis factor (TNF)-α was 
associated with increased inflammatory activity, hepatic 
fibrosis and liver injury in CHC[15-17]. Meanwhile, TNF-α 
has been identified as the key molecule promoting the 
development of insulin resistance and diabetes during 
HCV infection, and patients with severe liver disease and 
HCC have a higher TNF-α/IL-10 ratio[18,19]. In patients 
co-infected with HCV and hepatitis B virus (HBV), 
plasma IL-6 concentrations were positively correlated 
with illness duration and viral load, whereas the IL-18 
concentration was positively correlated with ALT and 
AST levels and might evaluate the effect of IFN on the 
immune state[20,21]. The above results suggest that the 
level of inflammatory factors in hepatitis C patients 
might be used as a reference for disease progression 
during HCV infection and antiviral therapy.
Chemokines play a more extensive role in the 
pathogenesis of CHC-related liver diseases and are even 
considered markers and therapeutic targets in CHC[22]. 
Among the various chemokines, human IFN-induced 
protein (CXCL-10) is the most widely studied. In CHC 
patients, the levels of peripheral blood and liver CXCL-10, 
along with C-C motif ligand (CCL)-5, IFN-inducible T cell α 
chemo attractant (I-TAC) and macrophage inflammatory 
protein (MIP)-1α/1β, were increased markedly[5,23], 
whereas the level of CXCL-10 in hepatocytes was 
correlated with histological severity and hepatic lobule 
inflammation[14,24,25]. CXCL-10 also serves as a marker 
of viral response and therapeutic outcome since a high 
pretreatment level of CXCL-10 indicated the inhibition 
of CXC chemokine receptor (CXCR) 3-expressing T cell 
response, which leads to therapeutic non-responses[5,23]. 
This phenomenon is also confirmed in the following cases 
where the virus was controlled during treatment with an 
increased number of CD8+ cells expressing high CXCR3 
levels[26]. In addition, monocyte chemotactic protein-1 
(MCP-1), soluble adhesion molecule (sAM), CCL-20 and 
CXCL-9 were reported to predict the outcome of antiviral 
therapy in CHC patients[27,28]. Chemokine IL-8 was also 
induced by HCV, and patients who were biochemical 
non-responders to IFN therapy had higher pretreatment 
levels of IL-8 or high histologic activities[29,30]. Therefore, 
chemokine levels are important reference values for 
monitoring the natural course and progression of HCV-
related liver diseases and even identifying different 
treatment response rates before treatment[5]. 
However, these studies investigating the utility 
of inflammatory cytokines and chemokines for the 
prediction of treatment responses were based only on 
a small number of patients infected with limited HCV 
subtypes, most were based on IFN or IFN plus ribavirin 
therapy regimens, and the results did not preclude an 
epiphenomenon associated with the effects of IFN[23,27]. 
Therefore, the use of inflammatory cytokines and 
chemokines as indicators of the pathological progression 
of HCV infection and treatment efficacy has yet to be 
supported by more data from larger multivariate studies 
of patients, especially those treated with DAAs.
MECHANISMS OF HCV-INDUCED 
INFLAMMATION
Because of T-cell-mediated autologous hepatocytotoxicity, 
the spontaneous clearance of HCV infection is not 
only difficult to achieve but also increases the risk of 
progression to chronic hepatitis and liver injury[31]. In 
addition to this T-cell-mediated cytotoxic response, HCV 
infection alone also triggers inflammatory responses 
through a variety of strategies to aggravate the 
progression of liver diseases (Figure 1).
Inflammation responses triggered by interactions 
between host and HCV 
Unlike receptor-mediated HCV entry processes, the 
occurrence of inflammation in HCV infection relies on 
the recognition, binding and interaction of HCV RNA and 
protein components with pathogen pattern recognition 
receptors (PRRs) or other host cellular structures, which 
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Table 1  Potential inflammatory biomarkers of hepatitis C 
Biomarker Clinical relevance Ref.
TNF-α Promoting development of insulin resistance and diabetes during HCV infection; Hepatic TNF-α 
was associated with increased inflammatory activity, hepatic fibrosis, liver injury and HCC
[15-19]
IL-6 Evaluating the progression of CHC to cirrhosis; Plasma IL-6 positively correlated with illness 
duration and viral load in HBV/HCV co-infected patients
[13,20]
IL-8 Associated with interferon therapy non-response and high histologic activities in CHC patients [29,30]
IL-18 Plasma IL-18 concentration was positively correlated with ALT and AST levels in HBV/HCV co-
infected patients; A marker for evaluating the effect of IFN on the immune state
[20,21]
CXCL-9 Potential marker for evaluating the progression of CHC to cirrhosis [13,14]
CXCL-10 CXCL-10 level in hepatocytes correlated with histological severity and hepatic lobule inflammation; 
A marker of viral response and therapeutic outcome
[5,13,14,23,24]
TNF-α: Tumor necrosis factor-α; IL-6/-8/-18: Interleukin-6/-8/-18; HCV: Hepatitis C virus; HCC: Hepatocellular carcinoma; CHC: Chronic hepatitis C; 
ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; IFN: Interferon; HBV: Hepatitis B virus.
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dependent interaction between the TLR2 and HCV core 
or NS3 proteins triggers the TLR2-specific inflammatory 
pathway[36]. NS5A specifically activated the promoter of 
the TLR4 gene in both hepatocytes and B cells, thereby 
activating the signal transduction cascades from MyD88 
to IFN regulatory factor (IRF)-3 and stimulating nuclear 
factor (NF)-κB-mediated IFN-β and IL-6 secretion[37].
In addition to the host PRRs, HCV proteins can 
also interact with other cellular structures and activate 
inflammatory pathways. The binding of HCV E2 to CD81 
induced CCL-5 secretion possibly through activating 
mitogen-activated protein kinase (MAPK)[38]. The 
transient expression of HCV NS5B in mouse liver and 
human hepatocytes catalysed the production of small 
RNA species, which activated innate immune signalling 
via TANK-binding kinase (TBK) 1, IRF-3 and NF-κB, 
and eventually induced the production of IFNs and 
inflammatory cytokines[39]. HCV core protein, which 
in turn activate downstream immune- and inflammation-
associated signal transduction pathways.
Cell surface or internal PRRs, such as Toll-like 
receptors (TLRs) 1-10, can discern pathogens and 
activate canonical signalling pathways during immune 
and inflammatory responses. Virus-derived pathogen-
associated molecular patterns (PAMPs), HCV RNA and 
viral proteins could induce pro-inflammatory cytokine 
and chemokine production via several PRRs. For 
example, TLR3 recognized the HCV double-stranded 
RNA produced during HCV replication and activated 
TLR3 signalling, resulting in high releases of IL-8, CCL-5, 
MIP-1 and CXCL-10[32,33]. Macrophages uptake HCV 
RNA through clathrin-mediated endocytosis, which is 
independent of receptor and productive infection, and 
therefore trigger myeloid differentiation primary response 
(MyD) 88-mediated TLR7 signalling to induce pro-IL-
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Figure 1  Mechanisms of hepatitis C virus-induced inflammation. Hepatitis C virus (HCV) RNA triggers Toll-like receptor mediated nuclear factor (NF)-κB 
activation and inflammatory cytokine release, while HCV proteins mainly lead to oxidative and endoplasmic reticulum stress and potassium efflux, causing the Nod-
like receptor pyrin domain containing inflammasome activation. The released inflammatory factors bind to their corresponding receptors and then directly induce 
NF-κB activation or indirectly lead to signalling pathway mediated downstream inflammatory response. HCV: Hepatitis C virus; ERS: Endoplasmic reticulum stress; 
AP-1: Activating protein-1; ASC: Apoptosis-associated speck-like protein containing CARD; DAMP: Damage associated molecular patterns; mtDNA: Mitochondrial 
DNA; MyD88: Myeloid differentiation factor 88; NLRP3: Nod-like receptor pyrin domain containing 3; ROS: Reactive oxygen species; vRNA: Viral RNA; TLR: Toll-like 
receptor; TNF-α: Tumor necrosis factor-α; IL: Interleukin.
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is mostly implicated in liver disorders, activated signal 
transducer and activator of transcription (STAT) 3 in 
human hepatocytes, leading to subsequent immune 
activation, inflammation and tumorigenesis[40]. In short, 
the over-replication of HCV in host cells is accompanied 
by a broad and complex interaction of host and HCV 
components, eventually unbalancing signal transduction 
pathways, causing uncontrolled excessive inflammatory 
responses and further exacerbating disease progression.
Inflammasome activation upon HCV infection
An inflammasome is a large, multi-protein cytosolic 
complex that perceives intracellular danger signals, such 
as microbial pathogens, inflammatory diseases, cancers 
and metabolic and autoimmune disorders via Nod-like 
receptors (NLRs) and ultimately stimulates the production 
of the inflammatory cytokines IL-1β and IL-18[41,42]. Four 
NLR families, NLRP1, NLRP3, NLRC4 and AIM2, have 
been characterized to date. Among them, NLRP3, as the 
most extensively studied, responded to the host- and 
environment-derived molecules and pathogen-associated 
activators[41]. Increased levels of plasma IL-1β and IL-18 
in hepatitis C patients indicated an activation of the 
inflammasome during HCV infection[43].
Activation of the inflammasome and secretion of 
mature IL-1β and IL-18 during HCV infection require 
the integration of two signals. The first is known as 
signal 1, which occurs when the virus is detected by a 
PRR or cytokine receptor, resulting in the activation of 
NF-κB and consequent upregulation of pro-IL-1β and 
pro-IL-18 mRNAs. Signal 2 is that NLRP3 senses HCV, 
recruits the adaptor protein ASC (apoptosis-associated 
speck-like protein containing CARD) and induces the 
recruitment and autocatalytic activation of caspase-1. 
The activated caspase-1 processes cytosolic cytokines 
IL-1β and IL-18 precursors into mature secretory 
proteins[34]. Although HCV infection was reported to 
activate the inflammasome[35], the conclusions and 
proposed mechanisms differ across studies. Michael 
et al[34] demonstrated that HCV infection induced 
inflammasome activation and IL-18 and IL-1β secretion 
in monocytes and macrophages through the recognition 
of viral single-stranded RNA by TLR7 but failed to 
stimulate the inflammasome and cytokine production 
by lymphocytes, dendritic cells or hepatocytes. Other 
studies reported that no inflammasome activation was 
detected in HCV-infected Huh-7 cells[44,45], whereas 
Burdette et al[46] reported HCV-induced secretion of 
IL-1β in Huh7.5 cells via induction of inflammasome 
complex assembly involving NALP3, ASC and caspase-1. 
In addition, although a previous report suggested that 
reactive oxygen species (ROS) are not inflammasome 
effectors in HCV-infected hepatocytes[45], Chen et al[44] 
demonstrated that HCV-RNA transfected monocytes 
and THP-1 derived macrophages could activate the 
NLRP3 inflammasome in a ROS-dependent manner, and 
the process was independent on retinoic acid-inducible 
gene 1 (RIG-1). Alternative mechanisms for inducing 
inflammasomes were also reported in HCV infection. 
For instance, after macrophage phagocytosis of HCV, 
HCV induced potassium efflux and activated the NLRP3 
inflammasome for the processing and secretion of IL-
1β[35]. The HCV P7 protein is a kind of pH-sensitive proton 
channel, and the decrease of extracellular pH could 
enhance P7 activity and then stimulate signal 2 to induce 
the maturation and secretion of IL-1β from RAW264.7 
macrophages[47], whereas a report showed that high 
expression of P7 protein in Huh7.5 cells failed to induce 
IL-1β production[46].
Altogether, inflammasome activation triggered 
by HCV infection might depend on HCV RNA and the 
secondary effects during HCV replication, such as ROS 
generation, potassium efflux and P7 activity. However, 
the phenomenon of inflammasome activation and 
detailed mechanisms in response to HCV infection 
might vary across different cell types, and these data 
suggest that monocytes and macrophages are the main 
effector cells activated by the inflammasome after HCV 
infection.
Inflammatory cascade response in the hepatic 
microenvironment
Although hepatocytes are the major cell population in the 
liver and the targets of cells for HCV entry and replication, 
non-parenchymal cells in the liver, such as KCs and 
HSCs, also play key roles in HCV-induced liver diseases. 
KCs, which are hepatic macrophages and account for 
approximately 15% of the total cells in the liver[48], 
exhibit limited internalization of HCV via phagocytosis, 
leading to the production of pro-inflammatory cytokines 
and chemokines[35]. HSCs are activated after HCV 
infection and are associated with liver fibrogenesis, 
including collagen deposition and abnormal extracellular 
matrix remodelling[49]. Crosstalk among these three 
kinds of liver cells plus the recruited immune cells during 
HCV infection in the hepatic microenvironment mediates 
inflammatory cascade signalling and exacerbates disease 
progression (Figure 2). The icons in the figure are shared 
by Reactome[50].
The interaction between HCV-infected hepatocytes 
and HSCs enhances the inflammatory response to 
HCV infection[31]. For example, in the HCV-infected 
hepatocyte and HSC co-culture system, IL-1α secreted 
by HSCs enhanced CCAAT-enhancer-binding protein 
β-targeted downstream gene expression, leading to 
enhanced expression of IL-6, IL-8 and MIP-1α/1β[31]. 
Additionally, in the co-culture system of HCV replicon 
cells and HSCs, HCV replicon cells released transforming 
growth factor (TGF)-β1 into conditioned medium and 
thereby induced fibrogenesis in HSCs, which was 
characterized by increased production of procollagen α1 
(I) and procollagen α1 (III) and decreased expression 
of fibrinolytic matrix metalloproteinase (MMP)[51]. 
Exosomes, which are endosomal-derived vesicles, also 
mediate communication between hepatocytes and 
HSCs. Although exosomes secreted from HCV-infected 
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hepatocytes (HCV-exo) could transport small amounts 
of HCV RNA into HSCs, the quantity of HCV RNA carried 
into HSCs is gradually decreased because HSCs do not 
support HCV infection and replication[52,53]. However, 
one study found that the miR-19a carried by HCV-exo 
could target suppressor of cytokine signalling 3 (SOCS3) 
in HSCs, leading to STAT3-mediated TGF-β signalling 
activation, profibrotic marker high expression and 
enhanced inflammatory responses[52].
After HCV infection, the inflammatory cascades 
between HCV-stimulated macrophages and HSCs 
are also activated in the hepatic microenvironment. 
To mimic the effect of HCV in the blood circulation on 
hepatic non-parenchymal cells, Negash et al[35] exposed 
human THP-1 cell-derived macrophages and KCs to 
HCV in vitro and showed that they activated caspase-1 
expression and enhanced IL-1β/-18 secretion. Similarly, 
conditioned medium derived from HCV-exposed human 
THP-1 macrophages and KCs increased the expression 
of inflammatory (NLRP3, TNF-α, IL-1β, IL-6 and CCL-5) 
and profibrogenic (TGF-β1, collagen 4A1, MMP2 and 
α-smooth muscle actin) markers in primary human and 
immortalized HSCs (LX2 cells)[54]. Further study identified 
that the chemokine CCL-5 in this conditioned medium 
induced inflammasome activation and fibrotic marker 
expression in HSCs, whereas TNF-α but not IL-1β could 
only induce inflammasome markers[54]. These studies 
emphasize that inflammatory cascade reactions could 
occur between macrophages and HSCs through highly 
expressed inflammatory mediators during HCV infection.
Moreover, chemokines secreted by HCV-infected 
hepatocytes and HCV-internalized KCs recruit immune 
cells to the site of infection, leading to aggravation of 
the inflammatory response and even liver damage 
in CHC[47,55]. Other molecules, such as ROS and lipid 
peroxidation products produced by activated KCs or 
injured hepatocytes, could also induce the activation of 
quiescent HSCs[49]. The interactions between the HSCs 
and the immune cells recruited into the liver and the 
HCV-infected or exposed hepatocytes/macrophages 
mediate inflammation-related cellular signalling, 
together establishing a microenvironment of the liver 
in an excessively inflammatory state and continuing to 
exacerbate disease progression.
Exacerbation of the inflammatory response by oxidative 
and endoplasmic reticulum stress
Oxidative stress is characterized by excessive ROS 
accumulation in vivo. ROS includes radicals, such 
as superoxide anion (O2-∙), hydroxyl radical (OH•) 
and hydrogen peroxide (H2O2). Superoxide anions 
are mainly derived from the mitochondrial electron 
transport chain and catalysed into H2O2 and OH• by 
superoxide dismutase[56]. Hepatocytes have abundant 
mitochondria, which are the main source of ROS. 





















Figure 2  Inflammatory cascade responses in the hepatic microenvironment. Crosstalk among parenchymal cells (hepatocytes), non-parenchymal liver cells 
(Kupffer cells and hepatic stellate cells) and recruited immune cells (macrophages, mast cells, dendritic cells and natural killer cells) plus hepatitis C virus replication 
in the hepatic microenvironment mediates inflammatory cascade signalling and exacerbates liver injury and disease progression. HSC: Hepatic stellate cells; NK: 
Natural killer; HCV: Hepatitis C virus.
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HBV infection[57]. Upon HCV infection, oxidative stress 
is thought to occur because of the expression of viral 
proteins, changes in the activity of oxidative enzymes, 
depletions of antioxidants and the ensuing chronic 
inflammation[58]. HCV core protein interacts with the 
mitochondrial protein chaperone prohibitin, leading to 
impairment of mitochondrial respiratory chain function 
accompanied by ROS overproduction[59]. The intracellular 
expression of E1, E2, NS3 and NS5A also potently 
enhances ROS levels by increasing intracellular calcium 
influx and decreasing mitochondrial transmembrane 
potential[58]. In addition to mitochondria-derived ROS, 
cellular nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase also acts as an important source 
of ROS, generating superoxide anions by catalysing 
the oxidation of NADPH[60]. Among the seven Nox 
enzymes (Nox1-5, Dual oxidase Duox1 and Duox2), 
Nox1 and Nox4 induced in hepatocytes by infecting 
with HCV phenotype 2a and 1b or expressing HCV 
proteins contribute to ROS production[60,61]. In brief, 
ROS accumulation caused by HCV infection in the 
liver further leads to activation of the signalling factors 
phosphoinositide 3-kinase (PI3K), Janus kinase, MAPK 
pathways or transcription factor NF-κB, activator 
protein-1 (AP-1), STAT3, HIF-1α, PPAR-γ and Nrf2, and 
those pathways induce downstream inflammatory and 
immune responses[62-65].
HCV protein expression is also accompanied by strong 
endoplasmic reticulum stress (ERS). HCV structural 
and NS proteins are continuously processed in ER-
derived membrane structures[66,67], perturbing normal 
ER functions and inducing ER stress[67,68]. The unfolded 
protein response (UPR) is that cells respond to ERS by 
activating an adaptive cellular programme and alleviate 
ER stress by inducing protein folding and degradation 
in the ER and decreasing overall protein synthesis[66]. 
The UPR is mediated by three ER transmembrane 
proteins: cleavage of activating transcription factor 6 
(ATF-6), inositol-requiring enzyme 1 (IRE1) and PKR-
like endoplasmic reticulum kinase (PERK) and their 
downstream factors X-box binding protein 1 (XBP-1) 
and eukaryotic initiation factor 2α (EIF2α)[66]. The UPR is 
initially activated in HCV-infected Huh7.5.1 cells and HCV-
transgenic mice, resulting in the phosphorylation of IRE1, 
EIF2α and ATF-6, and splicing of XBP-1[69]. However, HCV 
RNA or protein per se also exerts the resistance for UPR, 
such as XBP-1 activity downregulation in HCV-expressing 
cells and PERK activity inhibition by HCV E2, leading to 
a reduction in ER-associated protein degradation and 
UPR-associated translational attenuation, respectively[66]. 
Virtually, there is an interaction between ERS and 
inflammation, and ERS might be both a trigger and 
a consequence of chronic inflammation[70]. NS5A 
expression in the ER triggers ERS and ultimately leads 
to the activation of STAT3 and NF-κB, and this pathway 
is sensitive to mitochondrial calcium uptake inhibitors, 
calcium chelators and antioxidants, therefore providing 
evidence for the role of ERS and oxidative stress in the 
activation of the inflammatory response during HCV 
infection[71]. Under severe ERS, the UPR activates the 
JNK/AKT pathway and phosphorylates NF-κB protein 
IκB kinase (IKK), leading to cleavage of IκBα and 
activation of NF-κB[70]. UPR-independent Ca2+ release 
and excessive ROS and ER chaperone GRP78 that leak 
into the cytosol were also proposed to activate NF-κB to 
induce inflammation[70]. In turn, inflammatory factors 
also exacerbate ERS and oxidative stress. For example, 
TNF-α induced intracellular excessive generation of ROS, 
which in turn induced ERS, whereas IL-1β and TNF-α also 
increased ERS in a nitric oxide dependent manner[72,73].
The ERS and oxidative stress networks interact 
with each other and therefore play a key role in local 
and systemic inflammatory responses. HCV infection 
triggers ERS and disrupts mitochondrial signalling 
and cytosolic redox homeostasis, thereby inducing 
oxidative stress and inflammation. ERS and oxidative 
stress might individually or concurrently stimulate or 
exacerbate inflammatory responses, and vice versa.
ANTI-INFLAMMATORY/
HEPATOPROTECTIVE THERAPY IN HCV 
INFECTION
DAAs have been used clinically for several years, 
and some limitations were reported, including drug-
resistance, low efficacy in cirrhotic patients, drug 
interactions, liver toxicities, HBV reactivation and skin 
reactions[6,74-77]. Anti-inflammatory/hepatoprotective 
agents have fewer side effects for the treatment of HCV-
induced liver injury, fibrosis, cirrhosis or even HCC, as 
demonstrated by their long-term use in liver health 
cares in many Asian countries[77-80]. Most of these agents 
are natural or naturally derived compounds, and many 
have anti-HCV effects. After DAA treatment, some 
patients are still subject to persistent disease progression 
and HCV relapse[81]. Therefore, anti-inflammatory/
hepatoprotective agents with anti-HCV activity might be 
a better treatment choice for preventing CHC progression 
to severe liver diseases when used in combination with 
or subsequent to DAA therapy. According to the chemical 
category and practical application in the clinic, we mainly 
focus on certain representative plant or plant derivate 
active constituents considered to be the most promising 
for anti-inflammatory/hepatoprotective therapy in HCV 
infection, including the flavonoid compound silibinin, 
terpenoid compound andrographolide, polyphenols 
compound curcumin, alkaloids oxymatrine and herb-
derived antioxidant bicyclol (Figure 3)[77,78,80].
Silibinin
Flavonoids or bioflavonoids are found in numerous 
plants, and over 4500 flavonoids or their subgroups 
have been identified to date, of which silymarin and 
silibinin are representative compounds[77,80]. Silymarin 
is extracted from the seeds of the milk thistle Silybum 
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marianum and comprises at least seven flavonolignans 
(silybin A, silybin B, isosilybin A, isosilybin B, silychristin, 
isosilychristin and silydianin) and one flavonoid 
(taxifolin)[81,82]. Silibinin (formerly named silybin) is the 
major bioactive compound of silymarin and is widely 
used for the treatment of insulin resistance, alcoholic/
non-alcoholic liver disease and viral hepatitis because of 
its antioxidative, anti-inflammatory, anti-proliferative and 
immunomodulatory properties[81-84]. In vitro and in vivo 
studies showed that silymarin/silibinin could stimulate the 
expression of lysophosphatidylcholine acyltransferase, 
reduce the level of liver cirrhotic platelet-activating factor 
or block the activation of major signalling pathways, 
such as NF-κB and TGF-β signalling, thus limiting de 
novo fibrogenesis-related inflammation and preventing 
carcinogenesis in HCC[82,85]. Moreover, silymarin and 
silibinin were found to inhibit HCV infection in cell cultures 
by blocking viral entry, fusion, RNA and protein synthesis, 
N5SB polymerase activity and transmission[84]. Although 
oral administration of silymarin had little effect on liver 
enzyme activity and viral load in HCV-infected patients 
due to its rapid metabolism and low bioavailability[86-88], 
intravenous injection of water-soluble, succinate-
conjugated silibinin formulations showed significant 
antiviral effects in CHC patients who failed to treatment 
with the standard pegylated IFN/ribavirin therapy[89,90].
Other flavonoids, such as epigallocatechin-3-gallate, 
naringenin, quercetin, luteolin and apigenin, also have 
potential anti-HCV activities, hepatoprotective and anti-
inflammatory activities[77,91,92]. Therefore, these agents 
are expected to be developed for the treatment of 
hepatitis C patients with advanced liver diseases.
Andrographolide
Among the various secondary metabolites produced 
by plants, terpenoids are phytochemicals with potential 
therapeutic applications for the treatment of liver cancer, 
of which labdane diterpenoid compound andrographolide 
Promising anti-inflammatory/hepatoprotective agents for chronic hepatitis C
Compound Chemical 
category
Formula Chemical structure Mechanism of anti-HCV Major ani-inflammatory/
hepatoprotective activity
Ref.
Silibinin Flavonoids C25H22O10 Block viral entry, fusion, 
RNA and protein synthesis, 




and immunomodulation; Limit 
de novo fibrogenesis-related 
inflammation and prevent 
carcinogenesis in hepatocellular 
carcinoma.
[81-83,85]
Andrographolide Terpenoid C20H30O5 Inhibit HCV protein synthesis, 
RNA replication and infection; 
Activate the antiviral IFN 
response and suppress HCV 
NS3/4A protease activity.
Scavenge free radicals, decrease 
lipid peroxidation, regulate 
immune responses and prevent 
infection and cancer; Depletion 
of glutathione, induction of 
cytochrome P450, normalization 
of the levels of hepatitis markers.
[78,93,96-98,101]
Curcumin Polyphenol C21H20O6 Inhibit HCV replication by 
inducing HO-1- and AKT-
related signaling pathways; 
Block viral entry into human 
hepatocytes.
Suppress severe cytokine storm, 
alleviate liver injury or fibrosis, 
inhibit HSC activation, suppress 
activation of leptin signaling, 
enhance AMP-activated protein 
kinase activity.
[79,105-112]
Oxymatrine Alkaloids C15H24N2O2 Inhibit HCV replication by 
destabilizing heat stress 
cognate 70 mRNA and 
downregulating the expression 
of Hsc70.
Reduce serum transaminase 
or alkaline phosphatase level, 
modulate TLR4-dependent 
inflammatory pathways, 
attenuate liver injury and 
improve experimental hepatic 








C19H18O9 Decrease HCV load in the 
clinic without reported 
mechanism.
Exert hepatoprotective and 
anti-inflammatory effects in 
chemical-, immunological-, 
fatty-, drug-induced and 
surgery-caused liver injury 
animal models; Prevent hepatic 
fibrosis induced by CCl4, 
dimethylnitrosamine, bovine 
serum albumin and bile duct 
ligation.
[127,134,136-139]
Figure 3  Promising anti-inflammatory/hepatoprotective agents for chronic hepatitis C. HCV: Hepatitis C virus; IFN: Interferon; NS: Non-structural; HO-1: Heme 
oxygenase-1; TLR: Toll-like receptor.
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(C20H30O5) is isolated from the stem and leaf of 
Andrographis paniculata and was initially used to treat 
upper respiratory tract infections with good safety but was 
later reported to have anti-inflammatory/hepatoprotective 
effects[78,79]. Its mechanisms of action are mainly via 
scavenging free radicals, decreasing lipid peroxidation, 
regulating immune responses and preventing infection 
and cancer[78,93]. In vitro and in vivo, the anti-inflammatory 
activities of andrographolide were attributed to the 
attenuation of the protein kinase C, extracellular signal-
regulated kinase (ERK)1/2 or PI3K/AKT pathways, leading 
to the inhibition of NF-κB signalling pathway activation[93-95]. 
The anti-hepatotoxic activities of andrographolide were 
correlated with depletion of glutathione, induction of 
cytochrome P450 or normalization of the levels of hepatitis 
markers such as alkaline phosphatase and glutamic 
pyruvate transaminase[96-98]. The synthetic analogues 
of andrographolide exhibit analgesic, antipyretic and 
anti-inflammatory effects without notable toxicity in 
animal models[99,100]. Moreover, andrographolide was 
reported to inhibit HCV protein synthesis, RNA replication 
and infection[101]. Detailed mechanisms showed that 
andrographolide activates p38 MAPK phosphorylation 
and stimulates Nrf2-mediated heme oxygenase (HO)-1 
expression, thereby increasing the amounts of its 
metabolite biliverdin, which was found to activate the 
antiviral IFN response and suppress HCV NS3/4A protease 
activity[101,102]. These findings support a clinical trial of 
andrographolide and its derivatives for the treatment of 
severe CHC.
Curcuminoids
Curcumin, a hydrophobic polyphenol derived from the 
rhizome of the herb turmeric (Curcuma longa), has been 
widely used as a spice and colorant in foods[103]. To date, 
extensive clinical studies have proven its pharmacological 
properties of anti-inflammatory, antioxidant, antiviral, 
anticancer, hypoglycaemic, wound-healing and 
antimicrobial activities and showed that curcumin is safe 
and well tolerated[104]. In view of these observations, 
curcumin is predominantly used to treat inflammatory 
diseases via multiple mechanisms involving inflammatory 
transcription factors, cytokines, redox status or protein 
kinases[105]. Curcumin suppresses the severe cytokine 
storm caused by infection with severe viruses, such as 
HIV, HSV, HBV and HCV, and might be potentially useful 
to treat inflammation induced by Ebola virus infection[106]. 
For its hepatoprotective property, curcumin alleviates 
liver injury or fibrosis by targeting platelet-derived growth 
factor-β receptor, TGF-β, TLRs, MMPs and peroxisome 
proliferator-activated receptors and decreasing 
inflammatory cytokines[78]. In vitro studies showed 
that curcumin inhibits HSC activation via preventing 
leptin from increasing intracellular glucose levels[107], 
suppressing advanced glycation end-product-dependent 
activation of leptin signalling[108] or enhancing AMP-
activated protein kinase (AMPK) activity[109] and therefore 
reduces liver fibrosis. In addition, evidence suggests that 
curcumin has anticarcinogenic and chemopreventive 
effects through arresting the cell cycle and/or inducing 
apoptosis in a p53 dependent manner[103], as well as by 
activating caspase cascades[105]. Curcumin also inhibits 
HCV replication by inducing HO-1- and AKT-related 
signalling pathways[110,111] or by blocking viral entry 
into human hepatocytes[112]. Therefore, based on the 
available pharmacological data obtained from in vitro 
and in vivo studies, as well as clinical trials, there is an 
opportunity to translate curcumin into clinics for therapy 
of CHC with hepatic cirrhosis and HCC in the near future.
Oxymatrine
Oxymatrine and its active metabolite matrine are 
the major alkaloid aqueous extracts from the root of 
Sophora flavescens, Sophora tonkinensis and Sophora 
alopecuroides[113]. Clinically, oxymatrine has been used 
to treat chronic hepatitis B and leukopenia caused by 
tumour radiotherapy and chemotherapy in China[113,114]. 
In recent years, many laboratory and clinical trials have 
also shown the antiviral activity of oxymatrine against 
HCV in cell cultures and human studies[115-117]. Oxymatrine 
or its derivatives destabilize heat stress cognate 70 
(Hsc70) mRNA and thereby downregulate the expression 
of Hsc70[118-120]. As Hsc70 is packaged into HCV particles 
and becomes a structural component of the virus in the 
assembly process, oxymatrine or its derivatives could 
inhibit HCV replication[118,121]. Oxymatrine could also 
inhibit inflammatory activity as defined by reducing 
serum transaminase or alkaline phosphatase levels, 
modulating TLR4-dependent inflammatory pathways, 
attenuating liver injury and improving experimental 
hepatic fibrosis by downregulating fibrosis-related gene 
expression, decreasing collagen deposits, inducing 
apoptosis of HSCs or inhibiting lipid peroxidation[122-126]. 
Furthermore, accumulating research suggests that 
oxymatrine has anticancer effects, which might have 
therapeutic effects on HCC caused by HCV infection, but 
could also be used in the treatment of chemotherapy-
induced hepatotoxicity[127,128]. Therefore, oxymatrine 
is expected to be used in CHC patients with liver 
inflammation or injury and could improve chemotherapy-
induced hepatotoxicity or increase the survival rate of 
HCC patients. 
Bicyclol
To date, although the effects of ROS and the host 
redox system on HCV replication remain unclear[56,63] 
and different antioxidants show controversial anti-
HCV effects[63,129-131], clinical evidence suggests that 
antioxidant therapy might alleviate necroinflammation 
and fibrosis progression[131,132]. Classical antioxidants, 
such as glutathione (GSH)[63], N-acetyl cysteine (NAC)[133] 
and vitamin E[130], have been reported to treat hepatitis 
C with efficacy. In addition, bicyclol (4,4’-dimethoxy-
5,6,5’,6’-bis(methylenedioxy)-2-hydroxymethyl-2’-
methoxycarbonyl biphenyl), a synthetic compound 
derived from schizandrin C extracted from the Chinese 
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medicinal herb Fructus schisandrae, has potent 
antioxidative and certain anti-HCV effects in the clinic 
with safety[134,135]. Clinically, bicyclol tablets are used 
in many countries to treat various non-viral hepatitis 
and chronic hepatitis B and C accompanied by mild 
and moderate serum aminotransferase abnormality. 
Preclinical pharmacological experiments also showed that 
bicyclol exerts hepatoprotective and anti-inflammatory 
effects in chemical-, immunological-, fatty-, drug-induced 
and surgery-caused liver injury animal models[135]. 
Bicyclol also prevents hepatic fibrosis induced by CCl4, 
dimethylnitrosamine, bovine serum albumin and bile 
duct ligation[136-139]. Although the detailed mechanism 
varies in different models, the overall effect of bicyclol is 
derived from stabilizing mitochondrial and hepatocyte 
membranes, scavenging free radicals, reducing lipid 
peroxides, enhancing antioxidant gene expression or 
activity or inhibiting liver cell apoptosis, and thus achieves 
anti-inflammatory, antioxidant and liver cell-protective 
activities [135,140]. These effects of bicyclol and its antiviral 
activities make bicyclol a promising drug for treating CHC 
patients with liver injury or co-infection with HBV.
CONCLUSION
Inflammation is a common feature of most liver diseases, 
and inflammatory cytokines and chemokines produced 
after HCV infection accelerate hepatocyte damage 
and liver disease progression. HCV infection triggers 
inflammation through various mechanisms including 
pathogen pattern recognition, inflammasome activation 
and intrahepatic inflammatory cascades, while oxidative 
and ER stress coexist with and exacerbate inflammation 
and liver injury (Figures 1 and 2). HCV infection is a 
predisposing factor in the pathological process, but 
the long-term inflammatory responses and oxidative 
stress induced by the virus might further destroy the 
liver microenvironment and cause irreversible liver 
tissue damage[7,11]. Direct antiviral therapy might not be 
sufficient to stop the progression of liver disease in the 
context of inflammation, oxidative stress, liver tissue 
damage and metabolic dysregulation. Although anti-
inflammatory/hepatoprotective drugs might not provide 
a fast-acting remedy for the treatment of HCV infection 
as DAAs do, they can serve as an adjunct to DAAs by 
exerting comprehensive effects. These effects include 
the following: (1) decreasing uncontrolled inflammatory 
cytokine and chemokine levels; (2) directly protecting 
against oxidative stress or enhancing antioxidant 
gene expression; (3) restoring mitochondrial function, 
regulating liver enzyme levels and protecting against 
liver cell damage; (4) inhibiting HCV replication; and 
(5) improving the efficacy of IFN antiviral therapy in 
vivo[80,129,141]. Given the status of excessive inflammation 
and liver microenvironment dyshomeostasis in chronic 
HCV-infected patients, care for hepatitis C should extend 
beyond merely achieving an SVR to encompass an anti-
inflammatory/hepatoprotective strategy concurrently with 
or after DAA therapy. Meanwhile, their anti-HCV effects 
could prevent HCV relapse after the DAA treatment.
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